Orally active adenosine kinase inhibitors

US5763597A · kind A · utility

Assignee

• Metabasis Therapeutics, Inc. · US

Inventors

• Bheemarao G. Ugarkar · Escondido, US
• Mark D. Erion · Del Mar, US
• Jorge E. Gomez Galeno · Village of La Jolla, US
• Angelo Castellino · San Diego, US
• Clinton E. Browne · Oceanside, US

Key dates

• Filing date: Jun 7, 1996
• Grant date: Jun 9, 1998
• Expiry date: Jun 7, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo2,3-d! pyrimidine and 3-aryl pyrazolo3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.